Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Foghorn Therapeutics, Inc.

< Previous 1 2 Next >
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Announces CFO Departure
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Announces Chief Medical Officer Succession
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Provides an Update on FHD-609
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics to Present Preclinical Data from Its Selective CBP and EP300 Protein Degrader Programs and Preclinical Data for FHD-286, a Potent, Selective Inhibitor of BRG1 and BRM, at the 2023 American Association for Cancer Research Annual
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics to Participate at Cowen’s 43rd Annual Health Care Conference
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Announces New Preclinical Data for FHD-286 in AML to Be Presented at the American Society of Hematology Annual Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics to Participate at the Evercore ISI HealthCONx Conference
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics to Present at Connective Tissue Oncology Society Annual Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics to Present New Preclinical Data for BRG1/BRM Inhibitor FHD-286 in Combination with Anti-PD-1 Antibody at Society for Immunotherapy of Cancer 37th Annual Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
Foghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Selective CBP Program
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Tickers FHTX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.